UBE2Z

Across TCGA pan-cancer cohorts, UBE2Z Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated UBE2Z data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher UBE2Z Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2Z expression acts as an unfavorable survival marker.

ESCA, LIHC, and PRAD are the cancer types where UBE2Z Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.102	0.703	<.001	36	view →
LIHC	OS	Median	All	0.047	0.783	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

UBE2Z–ESCA (OS)

Open the ESCA breakdown →